These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30485867)

  • 1. The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis.
    Lin XQ; Wang P; Cai WK; Xu GL; Yang M; Zhou MD; Sun M; He F; He GH
    Pharmacopsychiatry; 2019 Sep; 52(5):222-231. PubMed ID: 30485867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
    Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
    Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report.
    Kuzin M; Scharrer I; Nolan D; Baumgartner M; Paulzen M; Schoretsanitis G; Xepapadakos F
    Basic Clin Pharmacol Toxicol; 2020 Oct; 127(4):354-357. PubMed ID: 32365274
    [No Abstract]   [Full Text] [Related]  

  • 5. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.
    Men X; Taylor ZL; Marshe VS; Blumberger DM; Karp JF; Kennedy JL; Lenze EJ; Reynolds CF; Stefan C; Mulsant BH; Ramsey LB; Müller DJ
    Clin Pharmacol Ther; 2024 May; 115(5):1065-1074. PubMed ID: 38284409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry.
    Berm E; Kok R; Hak E; Wilffert B
    Pharmacopsychiatry; 2016 Sep; 49(5):186-190. PubMed ID: 27101231
    [No Abstract]   [Full Text] [Related]  

  • 7. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
    Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
    Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
    Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
    JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).
    Berm EJ; Hak E; Postma M; Boshuisen M; Breuning L; Brouwers JR; Dhondt T; Jansen PA; Kok RM; Maring JG; van Marum R; Mulder H; Voshaar RC; Risselada AJ; Venema H; Vleugel L; Wilffert B
    Trials; 2015 Jan; 16():37. PubMed ID: 25636328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
    Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
    Ther Drug Monit; 2016 Feb; 38(1):127-34. PubMed ID: 26418700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences.
    Sicras-Mainar A; Guijarro P; Armada B; Blanca-Tamayo M; Navarro-Artieda R
    PLoS One; 2014; 9(11):e90453. PubMed ID: 25369508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.
    Castanares-Zapatero D; Gillard N; Capron A; Haufroid V; Hantson P
    Forensic Sci Int; 2016 Sep; 266():e48-e51. PubMed ID: 27328779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
    Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
    Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.
    Lessard E; Yessine MA; Hamelin BA; Gauvin C; Labbé L; O'Hara G; LeBlanc J; Turgeon J
    J Clin Psychopharmacol; 2001 Apr; 21(2):175-84. PubMed ID: 11270914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.
    Fukuda T; Yamamoto I; Nishida Y; Zhou Q; Ohno M; Takada K; Azuma J
    Br J Clin Pharmacol; 1999 Apr; 47(4):450-3. PubMed ID: 10233212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
    Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
    Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
    Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
    Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Zuojin Pill on the Metabolism of Venlafaxine in Vitro and in Rats and Associated Herb-Drug Interaction.
    Li Y; Li J; Yan D; Wang Q; Jin J; Tan B; Qiu F
    Drug Metab Dispos; 2020 Oct; 48(10):1044-1052. PubMed ID: 32561594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venlafaxine serum levels and CYP2D6 genotype.
    Veefkind AH; Haffmans PM; Hoencamp E
    Ther Drug Monit; 2000 Apr; 22(2):202-8. PubMed ID: 10774634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.
    Fukuda T; Nishida Y; Zhou Q; Yamamoto I; Kondo S; Azuma J
    Eur J Clin Pharmacol; 2000 May; 56(2):175-80. PubMed ID: 10877013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.